Lantern Pharma to repurchase 145K shares from Bios Entities at $3.44/share

Lantern Pharma Inc.

Company agreed to buy 145,348 common shares from Bios Fund I entities at $3.44/share, total ~$500K.
Bios Entities own ~14.7% of outstanding shares; sale for their own working capital and liquidity.
Transaction expected to close by November 30, 2023; customary reps, warranties, and covenants.
Buyback represents about 0.5% of shares outstanding (based on recent filings).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.